Preclinical data, combined with available experience in humans, have shown no evidence of ill effects in pregnancy of fenoterol or ipratropium. Nonetheless, the usual precautions regarding the use of drugs during pregnancy, especially during the 1st trimester, should be exercised. The inhibitory effect of Berodual/F UDV on uterine contraction should be taken into account.
Preclinical studies have shown that fenoterol HBr is excreted into breast milk. It is not known whether ipratropium is excreted in breast milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium would reach the infant to an important extent, especially when taken by aerosol.
However, because many drugs are excreted in breast milk, caution should be exercised when Berodual/F UDV is administered to a nursing woman.